SEC EDGAR · Company announcement
LRMR: Financial results
Filed 8-K for an event or period dated 2026-11-16. Financial results.
Follow LRMR- Became public
- Nov 16, 2026, 7:17 AM EST
- Event / period date
- Nov 16, 2026
- Collected
- Nov 16, 2026, 7:26 AM EST
Why this is connected
This filing identifies Larimar Therapeutics, Inc. as the issuer of the security. The company's SEC identifier connects it to LRMR.
Press Release issued by Larimar Therapeutics, Inc. on November 16, 2026* ↗Source evidence
Read the source excerpt or record
Item 2.02 Results of Operations and Financial Condition. On November 16, 2026, Larimar Therapeutics, Inc. announced its financial results and operational highlights for the third quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Press Release issued by Larimar Therapeutics, Inc. on November 16, 2026* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Furnished herewith SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: November 16, 2026 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: Chief Executive Officer
Price change after we could observe it
+7.69% LRMR
Adjusted closing prices from Nov 17, 2026 to Nov 19, 2026. SPY changed -1.70% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.